To evaluate the potential of DLX6-AS1 methylation as a noninvasive biomarker for the diagnosis of colorectal neoplasms, DLX6-AS1 methylation levels were measured in the peripheral leucocyte DNA of 60 CRC patients, 60 adenoma patients and 60 healthy controls. This evidence concerns the gene DLX6 and colorectal neoplasm.